---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Pharmacodynamics"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Pharmacodynamics. Topics: Huntingtin lowering in the striatum and cortex of humanized mice at 7 months, Greater lowering at the injection site than in the cortex, Huntingtin lowering and aggregate suppression in Q175 knock-in mice at 12 months, Motor coordination and survival in R6/2 mice after a single administration, and 9 further topics. 13 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Huntingtin lowering in the striatum and cortex of humanized mice at 7 months

> “We show that intrastriatal administration of AAV5-miHTT results in potent and sustained HTT suppression for at least 7 months post-injection.”
> “In the striatum, we observed a dose-dependent reduction of wtHTT with low, medium and high dose treatments resulting in 42%, 62% and 87% suppression at 7 months post-injection, respectively”
> “Moreover, a dose-dependent reduction of wtHTT was also observed in the cortex with low, medium and high dose treatments resulting in 16%, 33% and 62% reduction at 7 months post-injection, respectively”

Source: [Caron et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7145682/)

<a id="topic-2.1.2.6.2-2"></a>

### Greater lowering at the injection site than in the cortex

> “Consistent with intrastriatal delivery of AAV5-miHTT, we observed a significantly higher magnitude of both wt and mHTT lowering in the striatum compared to the cortex at 7 months post-injection”

Source: [Caron et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7145682/)

<a id="topic-2.1.2.6.2-3"></a>

### Huntingtin lowering and aggregate suppression in Q175 knock-in mice at 12 months

> “A significant dose-dependent average reduction of mutant HTT protein of up to 39% in the striatum and up to 13% in the cortex of Q175 KI mice 12 months after intrastriatal injection of AAV5-miHTT was detected”
> “AAV5-miHTT caused a dose-dependent and sustained HTT protein reduction with subsequent suppression of mutant HTT aggregate formation in the striatum and cortex.”

Source: [Spronck et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6446047/)

<a id="topic-2.1.2.6.2-4"></a>

### Motor coordination and survival in R6/2 mice after a single administration

> “AAV5-miHTT treatment showed a significant improvement in motor coordination on the rotarod by an increase in latency to fall of 22 s in the high-dose group, which is an increase of 56% compared with vehicle-treated R6/2 mice (one-way ANOVA, p = 0.0226; Figure 6B).”
> “One-time AAV5-miHTT administration resulted in a median survival improvement of over 4 weeks compared with untreated R6/2 HD mice.”

Source: [Spronck et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6446047/)

<a id="topic-2.1.2.6.2-5"></a>

### Mutant huntingtin messenger RNA and protein lowering in transgenic minipigs

> “Both human mutant huntingtin mRNA and protein were significantly reduced in all brain regions transduced by AAV5-miHTT.”
> “Consistent with the vector DNA and miHTT expression in the cortex, we also detected a significant reduction of 42.7% (SD ±25.4%; p = 0.0066) more distal in the cortex.”
> “This is the first demonstration of widespread human mutant huntingtin lowering in the large-animal model.”

Source: [Evers et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6127509/)

<a id="topic-2.1.2.6.2-6"></a>

### Mutant huntingtin protein lowering by brain region and in cerebrospinal fluid in minipigs at 6 and 12 months

> “Expression of miHTT strongly correlated with vector DNA, with a corresponding reduction of mutant HTT (mHTT) protein of more than 75% in injected areas, and 30 to 50% lowering in distal regions.”
> “CSF miHTT expression was detected up to 12 months, with CSF mHTT protein lowering of 25 to 30% at 6 and 12 months after dosing.”

Source: [Vallès et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33827977/)

<a id="topic-2.1.2.6.2-7"></a>

### Regional mutant huntingtin lowering reported by the sponsor at 12 months in minipigs

> “At 12 months, the most pronounced mHTT protein lowering was observed in the putamen (85%), caudate (80%) and amygdala (78%), followed by thalamus (56%) and cerebral cortex (44%).”

Source: [uniQure press release, preclinical publications (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-publications-preclinical-data-amt-130)

<a id="topic-2.1.2.6.2-8"></a>

### Huntingtin messenger RNA and protein lowering in patient-derived neurons

> “One-time AAV5-miHTT treatment significantly reduced human HTT mRNA by 57% and Htt protein by 68% in neurons.”

Source: [Keskin et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6849441/)

<a id="topic-2.1.2.6.2-9"></a>

### Reduction of exon 1 huntingtin messenger RNA and protein in two mouse models

> “Intrastriatal administration of AAV5-miHTT resulted in dose-dependent expression of mature miHTT microRNA in cortical brain regions, accompanied by significant lowering of both FL HTT and HTT1a mRNA expression at 2 months postinjection.”
> “Mutant HTT and HTTexon1 protein levels were also significantly reduced in the striatum and cortex of heterozygous zQ175 knock-in mice at 2 months after AAV5-miHTT treatment and in humanized Hu128/21 mice 7 months post-treatment.”
> “These data demonstrate that, in addition to FL HTT, AAV5-miHTT also effectively reduces the highly pathogenic HTTexon1 protein in HD.”

Source: [Sogorb-Gonzalez et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11629698/)

<a id="topic-2.1.2.6.2-10"></a>

### Neurochemical and volumetric markers in homozygous Q175FDN mice

> “High dose AAV5-miHTT treatment partially rescued tNAA depletion (P = 0.0003) (Fig. 6A), and tNAA concentrations in high dose-treated animals were restored to near-wild-type levels.”
> “AAV5-miHTT partially rescues regional volume loss in brains of 6-month-old homozygous Q175FDN mice”
> “Finally, gene expression analysis by RNA sequencing revealed a distinct transcriptional phenotype associated with mutant HTT expression in the striatum that was partially rescued by high dose AAV5-miHTT.”

Source: [Thomson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10232253/)

<a id="topic-2.1.2.6.2-11"></a>

### Plasma neurofilament light chain unchanged by treatment in homozygous Q175FDN mice

> “Plasma neurofilament light was elevated in homozygous Q175FDN mice (P < 0.0001) but was unchanged by AAV5-miHTT (Supplementary Tables 22 and 23), indicating that HTT lowering in the brain does not affect peripheral abundance of neurofilament light in this model.”
> “It is also possible that plasma neurofilament light may decrease with a longer treatment duration, and that our experimental timeline was too brief to capture the full effect of AAV5-miHTT therapy on this outcome measure.”

Source: [Thomson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10232253/)

<a id="topic-2.1.2.6.2-12"></a>

### Exploratory pharmacodynamic biomarkers in the U.S. study: mutant huntingtin and neurofilament light chain in cerebrospinal fluid

| Field | Quoted record |
| --- | --- |
| Exploratory outcome measure | “CSF Mutant Protein (fM)” |
| Exploratory outcome measure | “CSF/Serum Neurofilament Light Chain (pg/mL)” |
| Measure description of each | “Will be used as an exploratory biomarker to measure disease progression and responsiveness to AMT-130 treatment.” |

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-2.1.2.6.2-13"></a>

### Durability marker: engineered microRNA in cerebrospinal fluid extracellular vesicles up to two years in non-human primates

> “Quantifiable engineered microRNA levels enriched in extracellular vesicles were detected in the CSF up to two years after brain infusion.”
> “Altogether, these results confirm the long-term expression of adeno-associated viral vector serotype 5-delivered microRNAs and support the use of extracellular vesicle-associated microRNAs as novel translational pharmacokinetic markers in ongoing clinical trials of gene therapies for neurodegenerative diseases.”

Source: [Sogorb-Gonzalez et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8093922/)

> “After AAV treatment in non-human primates, the secretion of mature engineered microRNA molecules was confirmed, with extracellular microRNA levels correlating with viral dose and cellular microRNA expression in neurons.”

Source: [uniQure press release, preclinical publications (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-publications-preclinical-data-amt-130)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
